Noteworthy Stock: Bellerophon Therapeutics, Inc. (NASDAQ: BLPH)

Shares of Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) negotiated 248,835 shares against it an average volume of 973,104 shares. The stock concluded the recent trade at $0.9541 with upbeat/downbeat trend move of -5.53%. The company has total market value of 55.146M. The company has got a 52-week exceptional price of $3.3000 and reached a 52-week lowest of the share price at $0.4700. The daily trading range was observed between a day’s low price of $0.9201 to a day’s high price of $1.0110.

Bellerophon Therapeutics, Inc. (BLPH) recently provided a business update and stated financial results for the second quarter ended June 30, 2018.

Key Recent Highlights

  • PAH: Enrollment continues to progress well in the Company’s Phase 3 INOvation-1 study evaluating INOpulse® in patients with PAH. As before agreed upon with the FDA, a pre-specified interim analysis will be performed by the Data Monitoring Committee (DMC) when 75 subjects have completed the 16-week blinded treatment phase. The adaptive trial design allows the DMC to consider four potential recommendations following its unblinded review of the safety and efficacy data: stopping the trial early for efficacy, continuing to enroll the study as planned, increasing the targeted enrollment size if the original design is slightly underpowered, or stopping the study for futility or safety concerns. The Company is blinded to the results of the interim analysis and the DMC will only provide the recommendation to stop, continue or raise the trial size.  The evaluations for the subjects needed to conduct the interim analysis have been completed and the Company expects the readout of the interim analysis shortly.
  • PH-ILD: Following positive results in its Phase 2a study in PH-IPF, the Company is presently enrolling patients in a Phase 2b study evaluating INOpulse to assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in patients with PH-ILD. A total of 40 subjects will be randomized in the double-blind, placebo-controlled clinical study, which will include patients with idiopathic pulmonary fibrosis. The primary endpoint of the study is the change in 6 Minute Walk Distance (6MWD) and the study includes several additional endpoints, including improvement in right ventricular function. The Company expects top-line results from this study about the end of 2018.
  • PH-COPD: Following positive results from its Phase 2 study for INOpulse in PH-COPD, the Company, in conjunction with its steering committee, finalized the design of a Phase 2b study in PH-COPD.  Contract with the FDA has been reached on the design of this trial, which will be a double-blind, placebo-controlled study, and will enroll about 90 subjects.  The primary endpoint is change in 6MWD, with several additional secondary endpoints, including improvement in right ventricular function.

Second Quarter 2018 Financial Results


For the second quarter ended June 30, 2018, the Company stated a net loss of $11.5M, or $0.20 per share, contrast to a net loss of $3.9M, or $0.12 per share, in the second quarter ended June 30, 2017. On a diluted basis, the Company stated a loss of $0.20 per share for the second quarter ended June 30, 2018, contrast to a loss $0.15 per share, in the second quarter ended June 30, 2017.

Net loss for the second quarter of 2018 included an adjustment of $(3.7)M to the fair value of the Company’s ordinary stock warrant liability, as contrast to an adjustment of $2.4M in the second quarter of 2017.

Research and development expenses for the second quarter of 2018 were $5.8M, contrast to $4.7M in the second quarter of 2017. The raise was primarily Because of raised clinical trial activities and supply costs related to ongoing clinical programs.

General and administrative expenses for the second quarter of 2018 were $2.1M, contrast to $1.6M in the second quarter of 2017.  The raise was primarily Because of raised commercial and intellectual property consulting costs, and stock-based compensation expenses.

First Half 2018 Financial Results


For the six months ended June 30, 2018, the Company’s net loss was $7.4M, contrast to a $23.1M net loss stated in previous year period. Net loss per share was $0.13 in the six months ended June 30, 2018 contrast to a net loss of $0.70 in the previous year period. On a diluted basis, the Company stated a loss of $0.16 per share for the six months ended June 30, 2018, contrast to a loss of $0.70 per share in the previous year period.

Net loss for the six months ended June 30, 2018 included an adjustment of $3.4M in the fair value of the Company’s ordinary stock warrant liability, as contrast to an adjustment of $(12.0)M in the previous year period.

Research and development expenses for the six months ended June 30, 2018 raised to $12.2M, from $8.0M in the previous year period. The raise was primarily Because of raised clinical trial activities and supply costs related to ongoing clinical programs.

General and administrative expenses for the six months ended June 30, 2018 were $4.2M as contrast to $3.1M in the previous year period. The raise was primarily Because of raised commercial, intellectual property and financial consulting costs, and stock-based compensation expenses.

Return on assets ratio of the Company was -109.10%. The stock price switched up -13.10% 20-Days Simple Moving Average, dropped -3.00% from 50-Days Simple Moving Average and fell -50.68% from 200 Days Simple Moving Average. The company has price to cash ratio of 2.03.

 

Marcy Diaz

Marcy Diaz - Healthcare Marcy Diaz is a freelance writer and editor with more than 8 years’ experience in the profession and has conducted many training workshops in this field. She is a professional speaker on creative writing, digital publishing, and internet marketing. She lives in New York with her Husband and 2 kids. Marcy graduated with distinction from a reputable University in Marketing. She also teaches Marketing subject in New York. Marcy is a reporter of “Healthcare” Category. Address:  3695 Sugarfoot Lane Cayuga, IN 47928, United States of America Phone Number:  +1 765 492 5485 Email:  Marcy@dailynewsgallery.com

Leave a Reply

Your email address will not be published. Required fields are marked *